Establishment and Promotion of a Dyslipidemia Management and Control System Grounded on Hierarchical Medical Treatment

doi:10.12114/j.issn.1007-9572.2024.0231

Chinese General Practice ›› 2024, Vol. 27 ›› Issue (36): 4493-4497.DOI: 10.12114/j.issn.1007-9572.2024.0231

• Editorial Review • Next Articles

Establishment and Promotion of a Dyslipidemia Management and Control System Grounded on Hierarchical Medical Treatment

Department of Cardiology, Peking University First Hospital, Beijing 100000, China

Received:2024-06-25 Revised:2024-07-04 Published:2024-12-20 Online:2024-09-19
Contact: LI Jianping

立足分级诊疗的血脂异常管控体系的建立与推广

100000　北京市，北京大学第一医院心血管内科

通讯作者: 李建平

作者简介:

【专家简介】张龙，博士，北京大学第一医院心血管内科副主任医师，血脂亚组负责人，主持北京大学第一医院心血管内科"难治性高脂血症"专病特色门诊工作。主要临床方向：冠心病、心血管介入治疗；难治性高脂血症、家族性高胆固醇血症诊疗。科研方向：动脉粥样硬化人群队列研究，脂代谢紊乱队列研究。曾参与"十一五""十三五"国家科研项目及多项国家自然科学基金科研项目，"十四五"在研课题"中国高胆固醇血症的筛查与干预新靶点研究"骨干成员。在国内外专业杂志发表多篇SCI及核心期刊文章，研究成果曾多次在AHA、ECS等会议上被接收并展示。现任中国初级保健基金会心血管健康专业委员会常务委员兼秘书长，县域医院院长联盟县域慢病管理中心专家委员会委员，中国生物化学与分子生物学会脂质与脂蛋白专业委员会青年委员，《中国全科医学》杂志青年编委，《中国心血管病研究》杂志青年编委等。

【专家简介】李建平，主任医师、教授、博士生导师，北京大学第一医院副院长，心血管疾病研究所所长，血管稳态与重构全国重点实验室副主任，国家卫生健康委员会心血管分子生物学与调节肽重点实验室（北京大学）副主任，北京大学医学部血管健康研究中心副主任。现担任中华医学会心血管病学分会委员，中国医师协会心血管内科医师分会常务委员/高血压学组组长，中国医疗保健国际交流促进会常务理事和心血管健康医学分会主任委员，北京医师协会心内科专科医师分会副会长等学术任职。二十多年来一直从事冠心病介入治疗，开展高血压、高脂血症等动脉粥样硬化性疾病的相关临床和基础研究。尤其在H型高血压与脑卒中一级预防、无创冠状动脉功能学评估、空气污染中细颗粒物与早期动脉粥样硬化机制研究等方面结合我国人群特点开展研究，创新理论和实践，实现产业转化，做出突出贡献。牵头"十四五"国家重点研发项目"中国高胆固醇血症的筛查与干预新靶点研究"，先后主持1项国家科技支撑计划子课题和3项国家自然科学基金项目，主持首都卫生发展科研专项、北京市科技计划等省部级课题5项，以及2项北京大学医学部-密西根大学医学院转化与临床医学联合研究所项目，在Circ Res、Cardiovasc Res、Arterioscler Thromb Vasc Biol和Stroke等国际学术期刊发表SCI文章249篇，中文文章128篇；获1项国家科学技术进步奖二等奖，3项省部级奖励一等奖，1项省部级奖励二等奖等奖项。

基金资助:
国家重点研发计划(2021YFC2500600，2021YFC2500601)

Abstract

Abstract:

Dyslipidemia constitutes an essential risk factor for atherosclerotic disorders. From employing diverse types of blood lipid indicators as markers for risk prediction to subsequently applying low-density lipoprotein cholesterol as the primary lipid-lowering target in both primary and secondary prevention of cardiovascular diseases, relevant research and clinical practices indicate that the dyslipidemia management system grounded on hierarchical medical care is a significant measure for effective blood lipid control and efficient reduction of cardiovascular diseases. Continuously optimizing the prediction model for cardiovascular diseases, enhancing the construction of the medical consortium specializing in dyslipidemia disorders, and promoting the dyslipidemia management and control system based on hierarchical medical treatment will facilitate elevating the overall prevention and treatment level of dyslipidemia in China, and mitigate the health menace of cardiovascular diseases for Chinese residents.

Key words: Atherosclerotic cardiovascular disease, Dyslipidemia, Hierarchical medical treatment, Risk prediction

摘要：

血脂异常是动脉粥样硬化性疾病重要的危险因素。回顾历史，从把不同类型的血脂指标作为心血管疾病风险预测标志物，到以低密度脂蛋白胆固醇为主要降脂靶点应用于心血管疾病的一级预防及二级预防，相关研究和临床实践提示立足分级诊疗的血脂异常管控体系是进行有效血脂管控、切实降低心脑血管疾病的重要措施。不断优化心血管疾病预测模型、加强血脂异常专病医联体建设、推广立足分级诊疗的血脂异常管控体系将有助于提升我国血脂异常整体防治水平，达到心血管疾病防治的重心下沉、关口前移，降低心血管疾病对我国居民的健康威胁。

关键词: 动脉粥样硬化性心血管疾病, 血脂异常, 分级诊疗, 风险预测

ZHANG Long,LI Jianping. Establishment and Promotion of a Dyslipidemia Management and Control System Grounded on Hierarchical Medical Treatment[J]. Chinese General Practice, 2024, 27(36): 4493-4497. DOI: 10.12114/j.issn.1007-9572.2024.0231.
张龙,李建平. 立足分级诊疗的血脂异常管控体系的建立与推广[J]. 中国全科医学, 2024, 27(36): 4493-4497. DOI: 10.12114/j.issn.1007-9572.2024.0231.

References 35

[1]	ARNETT D K, BLUMENTHAL R S, ALBERT M A, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease：a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation，2019，140(11):e596-646. DOI：10.1161/CIR.0000000000000678.
[2]	VISSEREN F L J, MACH F, SMULDERS Y M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice：developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology（EAPC）[J]. Rev Esp Cardiol，2022，75(5):429. DOI：10.1016/j.rec.2022.04.003.
[3]	GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories，1990-2019：a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet，2020，396(10258):1204-1222. DOI：10.1016/S0140-6736(20)30925-9.
[4]	LUENGO-FERNANDEZ R, WALLI-ATTAEI M, GRAY A, et al. Economic burden of cardiovascular diseases in the European Union：a population-based cost study[J]. Eur Heart J，2023，44(45):4752-4767. DOI：10.1093/eurheartj/ehad583.
[5]	ZHAO D, LIU J, WANG M, et al. Epidemiology of cardiovascular disease in China：current features and implications[J]. Nat Rev Cardiol，2019，16:203-212. DOI：10.1038/s41569-018-0119-4.
[6]	TSAO C W, ADAY A W, ALMARZOOQ Z I, et al. Heart disease and stroke statistics-2022 update：a report from the American Heart Association [J]. Circulation，2022，145(8):e153-639. DOI：10.1161/CIR.00000000000010527.
[7]	TIMMIS A, VARDAS P, TOWNSEND N, et al. European Society of Cardiology：cardiovascular disease statistics 2021[J]. European Heart Journal，2022，43(8):716-799. DOI：10.1093/eurheartj/ehab892.
[8]	SAVJI N, ROCKMAN C B, SKOLNICK A H, et al. Association between advanced age and vascular disease in different arterial territories：a population database of over 3.6 million subjects[J]. J Am Coll Cardiol，2013，61(16):1736-1743. DOI：10.1016/j.jacc.2013.01.054.
[9]	KAPPERT K, BÖHM M, SCHMIEDER R, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk：analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease（TRANSCEND）and the Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial（ONTARGET）[J]. Circulation，2012，126(8):934-941. DOI：10.1161/CIRCULATIONAHA.111.086660.
[10]	TWIG G, YANIV G, LEVINE H, et al. Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood[J]. N Engl J Med，2016，374(25):2430-2440. DOI：10.1056/NEJMoa1503840.
[11]	胡盛寿，王增武. 《中国心血管健康与疾病报告2022》概述[J]. 中国心血管病研究，2023，21(7):577-600.
[12]	杨继，张垚，马腾，等. 1990—2019年中国心血管疾病流行现状、疾病负担及发病预测分析[J]. 中国全科医学，2024，27(2):233-244,252. DOI：10.12114/j.issn.1007-9572.2023.0470.
[13]	社区成人血脂管理中国专家共识撰写组. 社区成人血脂管理中国专家共识（2024年）[J]. 中华全科医师杂志，2024，23(3):220-228. DOI：10.3760/cma.j.cn114798-20231019-00260.
[14]	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（2023年）[J]. 中国循环杂志，2023，38(3):237-271. DOI：10.3969/j.issn.1000-3614.2023.03.001.
[15]	MORAN A, GU D F, ZHAO D, et al. Future cardiovascular disease in China：markov model and risk factor scenario projections from the coronary heart disease policy model-china[J]. Circ Cardiovasc Qual Outcomes，2010，3(3):243-252. DOI：10.1161/CIRCOUTCOMES.109.910711.
[16]	TRUETT J, CORNFIELD J, KANNEL W. A multivariate analysis of the risk of coronary heart disease in Framingham[J]. J Chronic Dis，1967，20(7):511-524. DOI：10.1016/0021-9681(67)90082-3.
[17]	ANDERSON K M, ODELL P M, WILSON P W, et al. Cardiovascular disease risk profiles[J]. Am Heart J，1991，121(1 Pt 2):293-298. DOI：10.1016/0002-8703(91)90861-b.
[18]	WILSON P W, D'AGOSTINO R B, LEVY D, et al. Prediction of coronary heart disease using risk factor categories[J]. Circulation，1998，97(18):1837-1847. DOI：10.1161/01.cir.97.18.1837.
[19]	D'AGOSTINO R B Sr, GRUNDY S, SULLIVAN L M, et al. CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores：results of a multiple ethnic groups investigation[J]. JAMA，2001，286(2):180-187. DOI：10.1001/jama.286.2.180.
[20]	D'AGOSTINO Sr, VASAN R S, PENCINA M J, et al. General cardiovascular risk profile for use in primary care：the Framingham Heart Study[J]. Circulation，2008，117(6):743-753. DOI：10.1161/CIRCULATIONAHA.107.699579.
[21]	LIU J, HONG Y L, D'AGOSTINO R B Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study[J]. JAMA，2004，291(21):2591-2599. DOI：10.1001/jama.291.21.2591.
[22]	吴兆苏，姚崇华，赵冬. 11省市队列人群心血管病发病前瞻性研究I危险因素水平与心血管病发病的关系[J]. 中华心血管病杂志，1999，27(1):5. DOI：10.3760/j:issn:0253-3758.1999.01.001.
[23]	王薇，赵冬，刘静，等. 中国35~64岁人群心血管病危险因素与发病危险预测模型的前瞻性研究[J]. 中华心血管病杂志，2003，31(12):902-908. DOI：10.3760/j:issn:0253-3758.2003.12.006.
[24]	刘静，赵冬，王薇，等. 中国多省市心血管病危险因素队列研究与美国弗莱明翰心脏研究结果的比较[J]. 中华心血管病杂志，2004，32(2):167-172. DOI：10.3760/j:issn:0253-3758.2004.02.020.
[25]	YANG X L, LI J X, HU D S, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population：the China-PAR project （prediction for ASCVD risk in China）[J]. Circulation，2016，134(19):1430-1440. DOI：10.1161/CIRCULATIONAHA.116.022367.
[26]	CLEEMAN J I, LENFANT C. The national cholesterol education program[J]. JAMA，1998，280(24):2099. DOI：10.1001/jama.280.24.2099.
[27]	Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. the expert panel[J]. Arch Intern Med，1988，148(1):36-69.
[28]	Summary of the second report of the National Cholesterol Education Program（NCEP）expert panel on detection，evaluation，and treatment of high blood cholesterol in adults（Adult Treatment Panel Ⅱ）[J]. JAMA，1993，269(23):3015-3023.
[29]	Adults Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program（NCEP）expert panel on detection，evaluation，and treatment of high blood cholesterol in adults（Adult Treatment PanelⅢ）[J]. JAMA，2001，285(19):2486-2497. DOI：10.1001/jama.285.19.2486.
[30]	STONE N J, ROBINSON J G, LICHTENSTEIN A H, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults：a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol，2014，63(25 Pt B):2889-2934. DOI：10.1016/j.jacc.2013.11.002.
[31]	GRUNDY S M, STONE N J, BAILEY A L, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol：a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation，2019，139(25):e1082-1143. DOI：10.1161/CIR.0000000000000625.
[32]	中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志，2007，35(5):390-419. DOI：10.3969/j.issn.1672-7185.2012.16.002.
[33]	中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南（2016年修订版）[J]. 中国循环杂志，2016，31(10):937-950. DOI：10.3969/j.issn.1000-3614.2016.10.00.
[34]	中华医学会，中华医学会杂志社，中华医学会全科医学分会，等. 血脂异常基层诊疗指南（实践版·2019）[J]. 中华全科医师杂志，2019，18(5):417-421. DOI：10.3760/cma.j.issn.1671-7368.2019.05.004.
[35]	中国血脂管理指南修订联合专家委员会，王增武，李建军，等. 中国血脂管理指南（基层版2024年）[J]. 中国全科医学，2024，27(20):2429-2436.

Establishment and Promotion of a Dyslipidemia Management and Control System Grounded on Hierarchical Medical Treatment

立足分级诊疗的血脂异常管控体系的建立与推广

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 35

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Jun, LUO Wen, WANG Luya, YANG Ya, CHEN Yan. Exploration and Practice of the Construction of Outpatient Model for Blood Lipid Management in Comprehensive Hospitals [J]. Chinese General Practice, 2024, 27(36): 4527-4533.
[2]	LI Yiguang, LIU Hejun, ZHAO Jinpeng, FENG Yan, XU Yinlan. Meta-analysis of the Effect of Carbohydrates on Cardiovascular Disease Risk Factors [J]. Chinese General Practice, 2024, 27(34): 4341-4349.
[3]	ZHENG Chuanlei, DING Ruicong, WANG Qi, GUO Yixing, LI Jian, HUANG Zhengchun, DONG Minghua, LUO Xiaoting, WU Qingfeng. Study on the Relationship between Dietary Patterns and Dyslipidemia among Residents Aged ≥35 Years: Based on the Gannan Chronic Disease Cohort Survey Data [J]. Chinese General Practice, 2024, 27(30): 3739-3745.
[4]	Beijing Hypertension Association, China Association of Gerontology and Geriatrics, Beijing Community Health Service Association, Beijing Community Health Promotion Association. Chinese Expert Consensus on Grassroots Prevention and Treatment of Hypertension Combined with Type 2 Diabetes Mellitus and Dyslipidemia in Adults 2024 [J]. Chinese General Practice, 2024, 27(28): 3453-3475.
[5]	ZHOU Zitong, JIA Yu, YAN Hong, XU Jialan, WEN Jun, WANG Siyu. The Prevalence of Dyslipidemia in Chinese Children and Adolescents: a Meta-analysis [J]. Chinese General Practice, 2024, 27(17): 2145-2154.
[6]	GAO Ying, XU Xinyi, LIU Yang, YANG Xiaokun. Research on the Development of Atherosclerotic Cardiovascular Disease Prediction Model for the Elderly Based on TCM Constitution [J]. Chinese General Practice, 2024, 27(15): 1878-1885.
[7]	LIU Wenjun, YAO Mi, JING Guanning, YAN Cunling, YAN Hui. Interpretation of Screening for Lipid Disorders in Children and Adolescents: U.S. Preventive Services Task Force Recommendation Statement [J]. Chinese General Practice, 2024, 27(15): 1796-1801.
[8]	LIU Caixia, AN Tingting, LIU Jing, LI Xiangyang, JIN Jie, XU Lanjuan. Prognostic Value of IMPACT and CRASH Models in the Assessment of Patients with Traumatic Brain Injury: a Comparative Study [J]. Chinese General Practice, 2024, 27(15): 1843-1849.
[9]	RAN Dongsheng, LU Yanyan, XIN Chunling, MA Yingcai. Research Progress on the Correlation of Dyslipidemia with Colorectal Serrated Lesions and Colorectal Cancer [J]. Chinese General Practice, 2024, 27(12): 1424-1430.
[10]	JIN Menglong, QIN Xiaoying, MALIYA Amiti, JIAZINI Nuerbai, LI Jianxin, CAO Jie, LUO Sifu, LIU Cheng, ZHANG Yuchen, GAI Mintao, LI Yanpeng, LU Xiangfeng, FU Zhenyan. Status and Influencing Factors of Dyslipidemia, Hypertension and Diabetes Comorbidities among Kazakhs in Xinjiang [J]. Chinese General Practice, 2024, 27(12): 1438-1444.
[11]	YUAN Xianxian, LI Jing, WANG Jia, ZHANG Kexin, YANG Ruihua, ZHENG Wei, LI Guanghui. Prevalence of Dyslipidemia in Pregnancy and Early Predictive Value of Blood Lipid Levels [J]. Chinese General Practice, 2024, 27(06): 670-678.
[12]	ZENG Senxiang, YANG Rui, DENG Xun, YANG Ruitao, YANG Xiaoyan. Management Standards of Polypharmacy in Type 2 Diabetes Combined with Atherosclerotic Cardiovascular Diseases in the Elderly [J]. Chinese General Practice, 2024, 27(05): 597-603.
[13]	LI Yaping, LI Xia. Research Progress of Correlation and Underlying Mechanisms between Metabolic Syndrome and Alzheimer's Disease [J]. Chinese General Practice, 2024, 27(03): 268-272.
[14]	LIANG Xiaoxian, YANG Jin, JIN Juzhen, ZHOU Jing, HU Jin, GAI Yun, DING Xiaoyun, WANG Junhua, WANG Ziyun. Association between Chronotype and Dyslipidemia among Population Aged 40-65 Years [J]. Chinese General Practice, 2023, 26(34): 4277-4282.
[15]	WEN Wen, ZHANG Kainan, CHEN Yulan, LI Yu, ZHANG Xiangyang. Correlation of Metabolic Indexes as Predictors with Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3740-3747.